Download your free eBook: Enhancing clinical trial success for pro-cognitive drugs in schizophrenia
Cognitive impairment associated with schizophrenia (CIAS) has a significant impact on patient wellbeing, which has substantial costs for both the patient and society in general.
Many pharmaceutical companies have conducted pro-cognitive drug trials in an attempt to address CIAS, but none have been successful. This leads us to question whether the compounds are simply ineffective or if methodological factors may be limiting progress.
In this eBook, we discuss the challenges facing pro-cognitive trials, and what they mean for drug development programmes, covering:
Key barriers in pro-cognitive trial designs, and how to overcome them
How patient recruitment strategies can improve trial outcome
How to select the right outcome measures to convincingly support trial claims
